Background:
Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine kinase overexpressed and activated in
different solid cancer; it showed important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In recent years different investigations highlight the importance of new Fak inhibitors as potential anti-cancer drugs, but other studies evidenced its role in different pathologies related to cardiac function or viral infection.
Methods:
An extensive bibliographic research (104 references) has been done concerning the structure of Fak, its importance in tumor development, but also in other pathologies currently under study. The compounds currently subjected to
clinical studies were therefore treated using the appropriate databases. Finally, the main chemical scaffolds currently under
preclinical investigation were analyzed, focusing on their molecular structures and on the activity structure relationships
(SAR).
Results:
At the moment only few reversible ATP-competitive inhibitors are under investigation in pre-clinical studies and
clinical trials. Other compounds, with different chemical scaffolds, are investigated to obtain more active and selective Fak
inihibitors. This mini-review is a summary of different Fak functions in cancer and other pathologies; the compounds today
in clinical trials and the recent chemical scaffolds (also included in patents) giving most interesting results are investigated.
In addition PROTAC molecules are reported.
Conclusion:
All reported results evidenced that additional studies are necessary to design and synthesize new selective and
more active compounds, although promising informations have been obtained from associations between Fak inhibitors and
other different anti-cancer drugs. In addition, the other important roles evidenced, both at nuclear level and in non-cancerous
cells, make this protein an increasingly important target in pharmaceutical chemistry.
4. How to Conduct Clinical Trials of Anti Cancer Drugs
